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There is increasing evidence that lung-resident memory T and B cells play a critical role in
protecting against respiratory reinfection. With a unique transcriptional and phenotypic
profile, resident memory lymphocytes are maintained in a quiescent state, constantly
surveying the lung for microbial intruders. Upon reactivation with cognate antigen, these
cells provide rapid effector function to enhance immunity and prevent infection.
Immunization strategies designed to induce their formation, alongside novel techniques
enabling their detection, have the potential to accelerate and transform vaccine
development. Despite most data originating from murine studies, this review will
discuss recent insights into the generation, maintenance and characterisation of
pulmonary resident memory lymphocytes in the context of respiratory infection and
vaccination using recent findings from human and non-human primate studies.
Keywords: lung, resident memory T cells, resident memory B cells, infection, vaccination, in situ optical
imaging, EVLPINTRODUCTION
Respiratory tract infections remain the leading overall cause of death in developing countries,
contributing to 5.4 million deaths annually (1) despite advances in vaccination uptake and
technology. Recent evidence has revealed resident memory lymphocyte populations play a key
role in the response to reinfection and the development of immune “memory”. Two populations of
circulating memory T cells with distinct effector and migratory properties were initially described:
central memory T cells (TCM) and effector memory T cells (TEM). Mechanistic studies in mice
demonstrated that TEM were more prevalent in tissues, while TCM were more prevalent in lymph
nodes (LN) and persisted following infection (2). TCM access and survey the LN for pathogens using
the LN homing receptors C-C chemokine receptor type 7 (CCR7) and CD62-L and have a high
proliferative capacity but exhibit low cytotoxicity (2–4). TEM lack or express low levels of CCR7 and
CD62-L but express receptors enabling access to peripheral tissues, where upon reencounter with
cognate antigen they rapidly exhibit high cytotoxicity (2–4). This concept has since been refined
after it was found that TEM are largely excluded from tissue and are restricted to the spleen and
intravascular compartment (4). A novel subset of memory T cells that share similarities to both TCMorg September 2021 | Volume 12 | Article 7389551
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identified as the predominant subset that re-circulate between
blood and peripheral tissues (4). It is now recognised that
additional subset designations exist, and memory T cells fall on
a continuum, rather than rigid subsets, based on their
localisation, trafficking, metabolism, longevity, and phenotypic
characteristics (5).
During the last decade, a memory T cell subgroup found to
reside long-term in tissues without recirculating in blood has been
identified. Lacking CD62-L and CCR7, resident memory T cells
(TRM) function as a first line of adaptive immune defence against
subsequent re-infection and constitute the majority of T cells within
the lung (5, 6). Lung-resident memory B cells (BRM) have also been
recently recognised for their critical role in immunity to respiratory
infection (7). Maintained in a quiescent state, BRM await secondary
challenge where they accelerate secondary B cell responses.
Humans frequently develop respiratory infections throughout
life and the current global coronavirus disease 2019 (COVID-19)
pandemic has highlighted the need to develop and distribute
effective vaccines to prevent/reduce key infectious respiratory
diseases. Therefore, the development of new vaccines (e.g.
COVID-19, respiratory syncytial virus, Middle East Respiratory
Syndrome coronavirus) and the improvement of existing
vaccines (e.g. tuberculosis, pertussis, pneumococcal and
influenza) able to induce long-lasting immunity and prevent
such diseases is urgently needed. The role of TRM and BRM in the
control of respiratory infections has been highlighted recently in
human and animal models (7, 8). Vaccination strategies that
enhance either pre-existing memory T and B cells or promote the
establishment of new antigen-specific TRM/BRM populations and
their maintenance, alongside novel techniques for their in situ
detection and functional characterisation, will be important tools
for developing vaccines that provide long-lasting immunity
against heterosubtypic infection. Here, we discuss the current
knowledge of pulmonary TRM and BRM in human and animal
models in the context of infection, highlighting knowledge gaps
and opportunities in vaccine development.FORMATION AND MAINTENANCE OF
PULMONARY TRM AND BRM
Generation of Pulmonary TRM
Professional antigen presenting cells (APCs) including dendritic
cells (DCs) are key regulators of innate and adaptive immune
responses. During primary viral/bacterial respiratory infection,
lung-resident DCs process and present the pathogen’s antigens
and migrate to the mediastinal lymph node (MLN) to prime
naïve T cells and stimulate their proliferation (Figure 1).
Migratory lung DCs within the MLN imprint T cell lung
homing through site-specific surface molecular signatures (15,
16) and help influence pulmonary TRM generation. In human
and humanized mice, pulmonary CD1c+ and CD141+ DCs have
both been shown to present viral antigens, however only CD1c+
DCs drive the expression of CD103 (a key marker of TRM – seeFrontiers in Immunology | www.frontiersin.org 2“Phenotypic Characterisation”) on both naïve and memory
CD8+ T cells (17). Multiple chemokine receptors involved in
lung trafficking are expressed by TRM including C-X-C Motif
Chemokine Receptor 3 (CXCR3), CXCR6 and CCR5 (11, 18–
20). Although no specific combination of homing markers have
been identified for pulmonary TRM, CD4
+ are likely recruited to
the airway during Respiratory Syncytial Virus (RSV) infection in
human via C-X-C motif chemokine 10 (CXCL10 - the ligand for
CXCR3), as chemokine levels correlated with activated CD4+ T
cell recruitment in bronchoalveolar lavage (BAL) (18).
Shortly after activation in the MLN, effector T cells migrate to
the lungs and contribute towards pathogen clearance. The
majority of pathogen-specific T cells then undergo apoptosis,
however a minority differentiate into TRM in response to
environmental cues (21), with the number of T cells persisting
in the lung following infection correlating with the efficiency of
TRM differentiation (22).
Effector T cells entering the lung express sphingosine-1-
phosphate receptor (S1PR1), sensing increasing sphingosine-1-
phosphate (S1P) gradients in blood and lymph, leading to tissue
egress (10). S1PR1 expression is regulated by local cytokine-
induced transcriptional downregulation and early activation
marker CD69-mediated post-transcriptional antagonism (10).
CD69 is a cell-surface receptor that is rapidly and transiently
expressed on all recently activated T cells. Induction of the
membrane‐bound type II C‐lectin receptor CD69 by antigen
stimulation and inflammatory cytokine exposure leads to
downregulation of S1PR1, which when combined with
inflammation-induced chemotactic signalling, supports effector T
cell retention and TRM generation (10, 23). Transition of recruited
effector T cells to TRM in murine lung requires simultaneous tissue
damage and T cell receptor (TCR) activation by pulmonary cognate
antigen encounter (24–27). Overlapping TCR genes from human
TRM and non-TRM indicate that environment, rather than epitope
specificity, drives TRM formation (19). Antigen-dependent cross-
competition however does promote TRM formation, with effector T
cells recognising antigen presented by infected tissue cells
preferentially entering the local TRM pool (28). Although
demonstrated in murine skin, it is possible the same rules also
apply to the lung. Naïve T cells in LNs may also be epigenetically
preconditioned during steady state conditions by migratory DCs to
differentiate into TRM upon exposure to cognate antigen (29).
Dependent on DC-driven, transforming growth factor b (TGF-
b), altering local or systemic TGF-b activity prior to vaccination
may help promote TRM formation (29).
Once established, TRM remain lung-resident and contribute
towards immunosurveillance and homeostasis (6). Maintained in
a quiescent state, human transplant studies have demonstrated
donor CD4+ and CD8+ TRM to persist in the lungs for over 15
months, with single cell transcriptome analysis confirming de novo
TRM generation via the identification of a “mature TRM” and an
immature “TRM-like” population that gradually acquire TRM
markers (CD69, CD103 and CD49a) over time (30, 31).
Pulmonary CD8+ TRM are however more short-lived than those
found in other tissues such as the skin and intestine (32, 33). As
microbes are constantly being inhaled, the limited longevity ofSeptember 2021 | Volume 12 | Article 738955
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unnecessary inflammation and pathogenesis in this tissue (34).
Gene Regulation in TRM
In human, Notch signalling alongside low levels of T-bet and
Eomesodermin (EOMES) are required for the development and
maintenance of CD4+/CD8+ TRM, with Notch regulating TRM
metabolic programs (11, 20). Human pulmonary CD8+ TRM
display elevated levels of the transcription factors Hobit (encoded
by the gene ZNF683) and Runx3, that may be involved in TRM
generation and/ormaintenance (30). Interestingly, despite showing
elevated mRNA levels, Hobit protein expression was reported
absent in human CD4+ TRM, suggesting differences between
CD4+/CD8+ TRM formation/maintenance (11).Frontiers in Immunology | www.frontiersin.org 3Heterogeneity in effector function and phenotype is evident
within TRM populations, particularly within CD4
+ TRM (19).
Transcriptome profiling of human lung CD69+ TRM has revealed
the differential expression of 31 core genes associated with
migration, adhesion and regulatory molecules when compared
to CD69- subsets (19). This transcriptional profile is conserved
across CD4+/CD8+ CD69+ lineages as well as tissues (19).
Pulmonary TRM exhibit high transcript levels for genes
encoding for several chemokine receptors, pro-inflammatory
cytokines and cytotoxic mediators, enabling them to be
recruited and retained within the lung and undergo rapid,
polyfunctional responses (11, 20). TRM respond rapidly with
effector functions, however, expression of regulatory genes (e.g.
cytotoxic T-lymphocyte-associated protein 4 [CTLA4] and B-FIGURE 1 | Pulmonary resident memory lymphocyte formation. 1) Inhaled respiratory pathogen (viral/bacterial) antigens are processed and presented by dendritic
cells (DCs) that migrate to the mediastinal lymph node (MLN). 2) DCs prime naïve CD4+ and CD8+ T cells in MLN with cognate antigen expressed on MHC II and
MHC I, respectively, resulting in T cell proliferation. B cells interact with cognate CD4+ T cells at the border between the B and T cell zones within Germinal Centres
(GCs), becoming short-lived, antibody-secreting plasma cells or early memory B cells (IgM+) or enter the GC and undergo somatic hypermutation and isotype
switching, with low affinity B cells differentiating into memory cells to ensure a degree of poly-reactivity. High affinity B cells differentiate into long-lived plasma cells
and migrate to the bone marrow where they secrete antibodies for decades (9). 3) Stimulation within the MLN leads to the expression of chemokine receptors
CXCR3, CXCR6 and CCR5 that enable T cell trafficking to the lung and airways following CXCL9/CXCL10/CXCL11/CXCL16 chemokine gradients. Pulmonary
epithelial cells, DCs and macrophages secrete CCR5 and CXCR3 binding chemokines following respiratory infection (10). The CXCR6 ligand, CXCL16, is also
expressed by lung bronchial epithelial cells and may also play a role in T cell homing (11). Memory B cells also migrate to the infected lung, following interferon-
inducible chemokines CXCL9, CXCL10 and CXCL11 via CXCR3 (12, 13) where they are strategically located for subsequent reinfection. 4) Once entered the lung,
effector T cells and short-lived plasma cells help clear infection and undergo apoptosis. A minority of effector T cells differentiate into pulmonary-resident memory T
cells (TRM). IgM
+ pulmonary-resident memory B cells (BRM) seed the lung early after infection, followed by isotype-switched BRM (7). 5) CD8
+ TRM accumulate and
self-renew in areas undergoing tissue regeneration following infection known as repair-associated memory depots (RAMD) where they seed airway CD8+ TRM, which
are ideally located for pathogen clearance in the case of reinfection. 6) CD4+ TRM and BRM reside within GCs of inducible bronchus-associated lymphoid tissue
(iBALT). Associated with prolonged persistence of antigens, iBALT GCs in infected lungs serve as sites for exaggerated B cell proliferation and cross-reactive clonal
selection of plasma cells/memory progenitors following B cell/CD4+ TRM interactions (14).September 2021 | Volume 12 | Article 738955
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present a safety mechanism to minimise aberrant activation and
associated inflammation/tissue damage (20).
Generation of Pulmonary BRM
Human antigen-experienced lungs are enriched with B cells
containing a resident memory phenotype (35). As human and
non-human primate (NHP) BRM data are limited, most findings are
derived from mouse studies. During primary respiratory infection,
naïve B cells, primed by either free antigen or antigen delivered by
subcapsular sinus (SCS) macrophages (36), interact with cognate
CD4+ T cells at the T-B border within the MLN (9, 37). Following
initial proliferation at the outer follicles, B cells may differentiate into
extrafollicular short-lived plasma cells, early (germinal centre (GC)-
independent) memory cells or proliferate to form the GC
(Figure 1). Following somatic hypermutation, B cells can exit as
long-lived plasma cells, migrating to the bone marrow where they
secrete antibodies for decades, or memory B cells (9, 37). Having
migrated to the lungs to participate in pathogen clearance, most of
the responding B cells undergo apoptosis, leaving a few resting
memory cells in the respiratory tract and lymphoid organs where
they wait for the same antigen.
Murine parabiosis studies have demonstrated BRM generation
requires local antigen encounter and is dependent on early
CD40-interactions with T cells (7). Once established, BRM
remain lung resident due to expression of CD69 (7). Here they
undergo metabolic reprogramming, switching from anabolic to
catabolic pathways to reduce their requirement for high levels of
cytokines for their maintenance (37). In mice, BRM are quiescent
and long-lived, maintained from precursors within persisting
GCs in areas known as inducible bronchus-associated lymphoid
tissue (iBALT) (14), however BRM have also been detected in the
absence of iBALT (39). Established one week after influenza
infection, murine pulmonary BRM have been demonstrated to be
phenotypically and functionally distinct from their systemic
counterparts (7).
Gene Regulation in BRM
Few studies have investigated gene regulation in pulmonary BRM,
particularly in humans. Although the possibility of a “master
transcription factor” for BRM generation has been suggested, no
unique transcription factor has been identified so far (9).
Increased expression of the transcription factors Bach2, KLF2,
ZBTB32, ABF1 and STAT5 are associated with BRM formation in
mice, however their exact roles are yet to be understood (9, 40).
The transcriptional regulation of pulmonary BRM differentiation
is likely to be unique – understanding these transcription factors
may help identify methods for modulating their formation (41).PHENOTYPIC CHARACTERISATION
Human and Non-Human Primate
TRM Markers
Due to their similarities to human, NHPs provide an invaluable
tool for investigating host response to respiratory infection andFrontiers in Immunology | www.frontiersin.org 4vaccination. Although heterogenous within the lung, human
and NHP TRM are phenotypically distinct from TCM and
TEM and are primarily identified by the high expression of
the C-type lectin receptor CD69, and integrins CD103 and
CD49a (30). The transmembrane CD69 is a key marker of
pulmonary TRM, distinguishing memory T cells in tissue from
those in circulation (19), however murine evidence suggests
its expression is not essential for the establishment and
maintenance of TRM in the lung (25, 42, 43). Although
considered as an early activation marker for TCR signalling,
TRM CD69 expression is not associated with markers of recent
activation and appears to be a function of previous antigen
exposure (19).
Preferentially expressed on CD8+ TRM compared to CD4
+,
CD103 promotes adherence to E-cadherin, an adhesion molecule
expressed by epithelial cells (22, 30, 44). CD103 expression is
driven by membrane-bound TGF-b (mediated by IL-10) on
APCs (CD1c+ DCs and monocytes) (17, 45) and is thought to
contribute towards initial recruitment and persistence of CD8+
TRM to aide surveillance rather than long-term maintenance
(42). CD49a, expressed by both CD4+ and CD8+ TRM, is an
integrin specific to collagen IV that facilitates locomotion for
surveillance and is essential for TRM survival by limiting
apoptosis following ligand engagement (42). Other recognised
surface markers of pulmonary TRM are outlined in Table 1 -
understanding the full function of these markers, whether they
represent different subsets/maturation states and whether they
are pathogen-dependent remains to be determined.
BRM Markers
Although no specific marker of BRM residency has been
described, pulmonary BRM are phenotypically distinct from
their systemic memory and non-memory counterparts (7) –
see Table 2. As well as lacking CD62-L, murine pulmonary BRM
express markers associated with TRM, such as CD69, CXCR3 and
CD44, which retain BRM within the lung (7, 12, 35, 39). CD69 has
also been found on human pulmonary BRM (35). Whether other
markers found in mice are also expressed on human and NHP
pulmonary BRM requires further investigation.
Functional studies have revealed BRM established early after
murine influenza infection are positive for immunoglobulin M
(IgM+) which are later followed by isotype-switched BRM (7).
Following murine pneumococcal infection, the majority of
isotype-switched BRM are IgG
+, with a small fraction IgA+ (35).
The majority of BRM found in healthy human lung are also
isotype-switched (35).ANATOMICAL LOCATION
TRM/BRM persist at sites of previous antigen encounter (13).
CD8+CD103+ TRM are found at higher frequencies in the airway
than in parenchyma due to adhesion to epithelial E-cadherin,
making them ideally located to respond to reinfection (30).
Murine CD8+ TRM reside and self-renew in peribronchiolar
foci in areas undergoing tissue remodelling, known as repair-September 2021 | Volume 12 | Article 738955
Humphries et al. Pulmonary-Resident Memory Lymphocytesassociated memory depots (RAMDs) (25, 38) (Figure 2). Tissue
damage is a requirement for RAMDs (25) and may have
implications for vaccine design and delivery. The existence of
human RAMDs containing CD8+ TRM remains to be confirmed.
CD4+ TRM and BRM are located and maintained around the
small airways within iBALT located within the parenchyma (13,
14, 25, 30) (Figure 2). iBALT contain GCs that serve as sitesFrontiers in Immunology | www.frontiersin.org 5for B cell selection and maturation following murine influenza
infection (50), generating cross-reactive memory B cells to
ensure heterosubtypic humoral protection (14). Formation is
associated with inflammation (44) and prolonged antigen
persistence (14). BRM have also been observed in non-
lymphoid areas below the airway epithelium and airways (13)
as well as lungs of pneumococcal-recovered mice lacking iBALT,TABLE 1 | Human and Non-Human Primate Surface Marker Expression on Pulmonary TRM.
Surface Marker Cell Type Function Pathogen/Condition Studied Species + References
CD69 CD4+ TRM Tissue retention Lung Donation, Mtb, RSV, Influenza Human (18, 19, 22, 24, 30, 46)
NHP (44)
CD8+ TRM Lung Donation, Mtb, RSV, Influenza Human (8, 18, 19, 22, 24, 30, 45, 46)
NHP (21, 44, 45)
CD103 (aE integrin) CD4+ TRM Adhesion to E-cadherin, initial
recruitment, facilitates persistence and
surveillance
Lung Donation, Mtb, biopsy, RSV, Influenza Human (11, 18, 19, 22, 24, 30, 46)
CD8+ TRM Lung Donation, Mtb, biopsy, RSV, Influenza Human (8, 18, 19, 22, 24, 30, 45, 46)
NHP (21, 45)
CD49a (a1b1 integrin/VLA-1) CD4+ TRM Adhesion to Collagen IV, limits
apoptosis, facilitates locomotion for
surveillance
Lung Donation, Mtb Human (19, 24, 30)
CD8+ TRM Lung Donation, Mtb Human (19, 24, 30)
CD49d (a4b1 integrin/VLA-4) CD4+ TRM Adhesion to Fibronectin Mtb Human (24, 47)
CD101 CD4+ TRM Inhibits T cell activation, proliferation Lung Donation Human (30)
CD8+ TRM Lung Donation, Mtb Human (19, 24, 30)
PD-1 (CD279) CD4+ TRM Immune checkpoint and T cell
exhaustion marker (prevent aberrant
activation)
Lung Donation, Mtb Human (19, 30)
NHP (48)
CD8+ TRM Influenza Human (19, 30, 46)
NHP (44)
CXCR3 CD4+ TRM Chemokine receptor Mtb, RSV Human (11, 18)
CD8+ TRM Biopsy Human (20)
CXCR6 CD4+ TRM Chemokine receptor Lung Donation, biopsy Human (11, 19, 46)
CD8+ TRM Lung Donation, biopsy Human (19, 20, 46)
CCR5 CD4+ TRM Chemokine receptor Lung Donation/cancer lobectomy, Mtb Human (11, 18, 46)
CD8+ TRM Mtb Human (46)
CCR6 CD8+ TRM Chemokine Receptor Lung Resection Human (20, 49)
CD44 CD8+ TRM Leukocyte rolling and adhesion Mtb, influenza Human (24)
CD28/CD28H CD8+ TRM T cell activation Lung Resection Human (11, 49)
CD45RO CD4+ TRM Memory T cell marker Influenza Human (33)
CD8+ TRM Lung donation, Influenza Human (22, 33)
CD45RA- CD4+ TRM Naïve T cell marker Lung Donation Human (19, 30)
CD8+ TRM Lung Donation Human (19, 30)SeptembeMultiple markers relating to adhesion/migration/activation are specifically upregulated on lung TRM. Other naive/effector/memory markers help distinguish memory T cells from regular
effector T cells (e.g. CD45RA and CD45RO). Mtb, Mycobacterium tuberculosis; RSV, Respiratory Syncytial virus.TABLE 2 | Surface Marker Expression of Human/Mouse Pulmonary BRM.
Surface Marker Function Pathogen/Condition Studied Species + References
CD38 Cell adhesion Influenza Mouse (12)
CD80 GC-matured memory marker Influenza, Pneumococcus Mouse (7, 12, 35, 39)
CD27 Post- activation marker, memory B cell marker Healthy lung resection/lobectomy Human (35)
CD73 GC-matured memory marker Influenza, Pneumococcus Mouse (12, 35, 39)
PD-L2 (CD273) GC-matured memory marker Influenza, Pneumococcus Mouse (7, 12, 35, 39)
CD20 B cell differentiation Pneumococcus Mouse (39)
CD69 Tissue retention Healthy lung resection/lobectomy, Influenza, Pneumococcus Human (35)
Mouse (7, 12, 35, 39)
CD44 Leukocyte rolling and adhesion Pneumococcus Mouse (35, 39)
CD11a Integrin, cell adhesion Pneumococcus Mouse (35)
CXCR3 Chemokine receptor Influenza Mouse (7, 12)r 2021 | VoluBRM surface markers are mostly associated with activation, GC-maturation and tissue homing and share some similarities with TRM.me 12 | Article 738955
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unremarkable lungs that may not require iBALT for their
maintenance (35, 39).FUNCTION
TRM Response to Viral Infection
Growing evidence indicates that virus-specific T cells resident
along the respiratory tract are highly effective at providing potent
and rapid protection against inhaled pathogens. In human
influenza infection, CD8+ TRM have been shown to recognise
the internal, conserved proteins of the virus whereas CD4+ TRM
recognise both internal and external proteins, with both cell
types contributing towards heterosubtypic protection (33). CD8+
TRM have been shown to be cross-reactive against three influenza
strains (51), with single cell sequencing revealing diverse TCR
profiles “capable of recognising newly emerging viral escape
variants” (22).
Influenza-specific CD8+ TRM have a low activation
requirement, requiring only cognate antigen in the absence of
helper cell-derived signals (52). Once stimulated, they are highly
proliferative, producing polyfunctional progeny (producing ≥2
cytokines – IFN-g, TNF, Granzyme B and IL-2) with effector
function superior even to their parent population (22, 44).
Polyfunctional TRM offer enhanced protection by producing
higher levels of cytokines whilst simultaneously driving effectorFrontiers in Immunology | www.frontiersin.org 6responses (53) - activated CD8+ TRM exert their cytotoxic
function to kill infected cells (10) whilst CD4+ TRM interact
with B cells in iBALT to generate new neutralising antibodies
(14, 54). A newly identified, long-lived CD4+ T resident helper
(TRH) population with functional and phenotypical similarities
to lymphoid T follicular helper cells (TFH) has also been
described following murine influenza infection. Residing within
iBALT, TRH are tightly localised with BRM to support local
antibody production following reinfection (55).
In an experimental human RSV infection model, the
abundance of RSV-specific, pulmonary CD8+ TRM before
infection was associated with reduced symptoms and viral
load, implying that CD8+ TRM can confer protection against
severe respiratory viral disease when humoral immunity is
overcome (8). RSV-specific CD8+ TRM displayed phenotypic
changes representative of advanced differentiation, with
downregulation of both co-stimulatory and cytotoxicity
markers, suggesting cells can respond rapidly to reinfection,
but function is restricted to minimise excessive tissue
damage (8).
RSV infection in African Green Monkeys (AGM) also
induced virus-specific airway CD8+ TRM capable of reducing
viral titres, however failed to induce robust CD4+ TRM and
humoral responses (21). Previously protective RSV-candidate
vaccines in AGM induced a strong T cell response, whilst those
eliciting a strong neutralisation antibody response without
detectable T cell response were not as effective (56). Similar toFIGURE 2 | Compartmentalisation of Pulmonary TRM and BRM. 1) CD8
+ TRM are maintained in repair-associated memory depots (RAMDs) located in peribronchiolar
foci in areas previously damaged from primary infection. RAMDs can be identified via the presence of cytokeratin-expressing cell aggregates which contain distal
airway stem cells that help reconstruct damaged lung tissue (10). Murine evidence suggests interstitial CD8+ TRM are primarily maintained by a process of
homeostatic proliferation and seed airway TRM, driven by CXCR6 in response to airway CXCL16 (38). 2) CD4
+ TRM surround BRM cell follicles in iBALT located within
the pulmonary parenchyma, where prolonged antigen persistence enhances CD4+ TRM/BRM formation. Just like RAMDs, iBALT requires tissue damage/inflammation
for their establishment. CD4+ TRM are then recruited to the alveolar space via CXCL10/CXCR3.September 2021 | Volume 12 | Article 738955
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CD4+ TRM recognise external proteins (18). RSV-induced
immunopathology relates to a dysregulated T cell response –
RSV-specific memory CD8+ T cells in blood display little
evidence of multiple cytokine production unlike those seen
against influenza (8, 18). CD8+ TRM however appear to be
more polyfunctional, generating IFN-g, IL-2 and TNF (21),
however fail to undergo proliferation when activated and
express reduced cytotoxicity markers compared to peripheral
memory cells (8).
TRM Reponses to Bacterial Infection
Activated CD4+ and CD8+ TRM have been identified in the lungs
of patients infected with Mycobacterium tuberculosis (Mtb),
where they help limit intracellular macrophage Mtb replication
(46). TRM were polyfunctional, expressing IFN-g, TNF ± IL-2,
and exhibited a highly cytotoxic profile, with CD4+ TRM
appearing more polyfunctional than CD8+ TRM (46). CD49d is
upregulated on airway CD4+ TRM and optimises the localisation
of human Mtb-specific recall responses (47). Mtb infection in
macaques drives a cellular T helper 1 (TH1) and humoral
response, without protective efficacy, however repeated
pulmonary Bacillus Calmette-Guérin (BCG) delivery was
shown to induce polyfunctional, TH17 CD4
+ TRM, leading to
airway IgA secretions in BAL (48), presumably through the
generation of BRM. Interstitial CD4
+ depletion with simian
immunodeficiency virus (SIV) following Mtb infection
identified CD4+ TRM (57), proliferating CD8
+ memory T cells
(TCM, TEM and likely TRM) and B cells within iBALT (58) as
critical for suppressing latent Mtb reactivation.
TH17 CD4
+ TRM are also critical in protecting against murine
nasal Bordetella pertussis (Bp) colonization (59). Although both
capable of protecting against Bp lung infection, whole cell Bp
vaccine, unlike the acellular vaccine, induced nasal IL-17-
producing CD103+ CD4+ TRM (similar to natural Bp infection)
that recruited neutrophils to enhance bacterial clearance.
TRM Bystander Effect
Lung TRM also display “innate-like” behaviour, amplifying
inflammation following noncognate bacterial infection. APC-
derived IL-12/IL-18 activated virus-specific CD8+ TRM within
the lung parenchyma, leading to the rapid synthesis of IFN-g.
This “bystander activation” boosted neutrophil recruitment to
improve bacterial clearance. Despite being performed in mice,
the authors demonstrated in vitro that human CD8+ TRM
similarly synthesise IFN-g in response to IL-12/IL-18 (60).
BRM Response to Viral and Bacterial
Infections
Alongside long-lived antibody-secreting plasma cells, BRM
contribute towards the protective humoral immune response
to pulmonary reinfection (12). The presence of BRM is a common
feature of antigen‐experienced lungs and is important for
acquired immunity (7). B cells in the airways secrete antibodies
that act both locally and at mucosal surfaces. These antibodies,
predominantly IgM and IgA, bind to glandular epithelial and
mucosal surfaces to promote pathogen clearance (61). B cellsFrontiers in Immunology | www.frontiersin.org 7activated in respiratory lymphoid tissue also differentiate into
IgA‐secreting plasma cells that predominantly act in the airway.
Current knowledge of B cell homing and class switching in the
airway remains limited.
Murine parabiosis/adoptive transfer/depletion studies have
demonstrated the protective role played by BRM in response to
both viral (7, 12, 54) and bacterial lung infection (35). BRM
provide rapid antibody-secreting cells (ASC), producing a range
of class switched neutralising antibodies (7, 12). Lung BRM
produce greater numbers of ASC than splenic memory cells
following exposure to drifted virus, indicative of heterosubtypic
protection (14). Cross-neutralising antibodies to conserved,
internal influenza proteins provide heterosubtypic protection
(14, 54). Although IgA is more effective than IgG at preventing
upper respiratory infection, in combination they achieve maximal
neutralising activity against influenza in mice (12). Following
murine pneumococcal infection, BRM contribute towards bacterial
clearance by rapidly secreting cross-reactive antibodies, even
when reactivated by a serotype-mismatched strain (35). In
macaques, iBALT persistence is associated with reduced Mtb
reactivation due to enhanced B-cell and humoral immunity
(58). BRM are also potent APC, binding and endocytosing
antigen via their BCR to increase peptide/MHC II presentation
and further enhance CD4+/B cell responses (9, 13).LOSS OF PULMONARY PROTECTION
Pulmonary immunity to respiratory pathogens wanes over time,
meaning individuals are susceptible to recurrent infections
throughout their lifetime. Although antigen drift may
contribute to loss of protection, the gradual loss of pulmonary
CD8+ TRM is a major contributor (32). Murine lung CD8
+ TRM
are less durable than those found in skin due to an increased
susceptibility to apoptosis (32), and have been shown to undergo
“retrograde migration” to the MLN where they provide longer-
lived regional memory (62). Loss of RAMDs due to tissue repair
correlated with a decline in CD8+ TRM number in mice (10, 25),
whilst in humans iBALT diminishes with age (6) which may
explain why older age groups are more susceptible to respiratory
infection due to a reduced ability to mount CD4+ TRM/
BRM responses.IMMUNOPATHOLOGY
Although TRM-driven immunopathology has been described in
other tissues (63), less is known regarding pulmonary TRM.
Moderate-severe asthma patients display increased numbers of
CD4+CD103+ TRM in their airways (64) and vaccine-enhanced
disease in children with formalin-inactivated RSV is driven by
TH2 CD4
+ memory cells that induce excessive inflammation
(65). Exacerbations of pulmonary pathology following RSV
infection have also been linked to iBALT which stimulate
increased, yet detrimental, immune responses (66). CD8+ TRM
may impact gas exchange via the presence of RAMD or throughSeptember 2021 | Volume 12 | Article 738955
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CD8+ T cells damage non-infected epithelial cells during
influenza infection through TNF and IFN-g release (67).
Although the detrimental effect due to TRM/BRM has not been
demonstrated in vivo, TRM/BRM formation may not always be
beneficial if accompanied by another immune cell influx such as
that found following acute infections.VACCINATION STRATEGIES TO
PROMOTE TRM
The presence of pathogen-specific TRM cells in the lungs has been
shown to correlate with protection in human and animal models.
It has therefore been proposed that TRM represent one of several
immune mechanisms that should be harnessed together for
optimal vaccine-mediated protection. A better understanding
of how lung TRM are generated and maintained is required for
optimal vaccine development. Vaccination strategies to promote
TRM have been successfully demonstrated in mouse models,
including engineered biomaterials that modulate antigen
delivery and retention time, adjuvant combinations, viral
vectors and virus-like particles, as well as direct APC targeting
(68), however studies in human and NHP are limited.
In mice and human, inactivated influenza vaccines induce
systemic humoral responses but fail to induce T cell immunity in
the lungs (33, 69, 70). Intranasal live-attenuated influenza virus
vaccines however generate mucosal IgA, lung CD4+ TRM and
virus-specific CD8+ TRM similar in phenotype to those generated
by influenza virus infection, providing long term, heterosubtypic
protection, independent of circulating T cells and neutralising
antibodies (70, 71). Tissue-resident alveolar macrophages have
been found to limit CD8+ TRM formation following murine
influenza infection and may offer an attractive target for
manipulation (72).
Intravascular, but not subcutaneous, administration of an
agonistic anti-CD40 antibody alongside poly-IC : LC (a Toll-like
receptor 3 activator) with HIV envelope peptide antigen directly
stimulated APCs in the blood, MLN and lung to enhance
pulmonary CD8+CD103+ TRM formation in macaques (45).
Intravenous BCG in macaques induces more antigen
responsive pulmonary CD4+ and CD8+ TRM than intradermal
administration, with protection lasting 6 months later (73).
Intratracheal boosting with BCG however following
intradermal BCG vaccination enhances protection (74).
Although this study only analysed peripheral blood to correlate
increased CD4+ TEM populations with improved protection, it is
anticipated that local delivery of antigen to the lungs would also
increase TRM/BRM populations. Pulmonary mucosal BCG
vaccination therefore offers superior protection against Mtb
compared to standard intradermal vaccination (48, 75, 76).
VPM1002, a live BCG vaccine genetically modified to
improve immunogenicity, outperforms live-attenuated BCG in
preclinical testing and is undergoing clinical trials
(NCT03152903) (77). Aerosol immunization with a mutated
Mtb strain MtbDsigH reduced bacterial burden and lungFrontiers in Immunology | www.frontiersin.org 8pathology when compared to aerosolised BCG following Mtb
challenge in macaques (78).MtbDsigH persisted for longer in the
lungs than BCG and generated increased iBALT and CD69+ T
cells in BAL, which likely include TRM. Since antigen is required
for TRM/BRM establishment, increasing its persistence enhances
generat ion. Increasing antigen persistence using a
cytomegalovirus vector encoding Mtb antigen inserts prevented
disease in macaques through the establishment and maintenance
of lung TRM (79).
It is also possible that skin-resident TRM generated through
intradermal vaccination may enhance both local and systemic
host responses to Staphylococcus aureus, a common commensal
of the skin and nasal mucosa, to help minimise Staphylococcal
pneumonia (80).VACCINATION STRATEGIES TO
PROMOTE BRM
Strategies to induce pulmonary BRM require delivery of antigen
to the lung (7). In mice, intranasal vaccination extended antibody
specificity to confer heterosubtypic protection by inducing GCs
that generated cross-reactive antibody responses (14). In human,
the squalene emulsion adjuvants AS03 or MF59 augmented
neutralising antibody production when co-administered
intramuscularly with influenza vaccine (81). Both adjuvants
enhanced antigen uptake and presentation in local tissue
leading to increased CD4+ and B cell responses, with AS03 also
shown to increase naïve B cell activation and the adaptability of
pre-existing memory B cells (82). Despite increasing the breadth
of B cell repertoire following seasonal Flu vaccine (83), the
impact of adjuvants on pulmonary TRM/BRM remains to be
demonstrated for such intramuscular vaccine. We could not
exclude that a boost from an adjuvanted vaccine in humans
previously exposed to a similar antigen encountered in the lung
could re-activate and maintain pulmonary TRM/BRM.
In contrast, certain respiratory viruses such as RSV are known
to trigger a TH2-like, dysregulated antiviral response (84). Acute
RSV infection limits pulmonary BRM formation (85) and encodes
a number of immunomodulatory proteins that impair antigen
presentation and type 1 interferon release (18), which may
explain why infection is associated with a low level antibody
response (21). Similarly, COVID-19 also suppresses MHC I/
MHC II antigen presentation and interferon response (86).
These issues of dysregulated T cell responses should be
avoided or overcome through vaccination, leading to long-term
humoral protection.QUANTIFYING IMMUNOLOGICAL
MEMORY FOLLOWING VACCINATION
Most vaccine studies in humans rely on peripheral blood
sampling to evaluate protection. Serum haemagglutination
inhibition (HAI), ELISA or ELISpot may indicate the humoral
response generated against a given pathogen/vaccine, howeverSeptember 2021 | Volume 12 | Article 738955
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has been seen despite the absence of HAI titres (87). Nasal IgA is
also a better reflector of protection to RSV than serum IgG (85).
Circulating memory T and B cells do not always correlate with
protection (8, 85) and immune responses can differ from those in
lung (44).
Limited peripherally accessible biomarkers have been
identified following immunization relating to resident memory
lymphocyte generation. Early rises in plasma IL-10 correlated
with pulmonary CD8+CD103+ TRM generation following
immunization in macaques (45). The CXCL10/CXCR3 axis has
also been postulated as a potential biomarker for CD4+
migration to the lung (18). Further immunization studies
correlating peripheral biomarkers with TRM/BRM formation
are required.
Airway TRM can be isolated via BAL (30). Virus-specific
CD8+ frequencies have been found to be 10 times higher in
BAL than in peripheral blood in AGM, highlighting the
quantitative differences between local and systemic T cell
responses (21). BAL can be collected multiple times, providing
temporal information on airway populations, but not interstitial.
Post-mortem analysis is often the only method for assessing
TEM/TRM. Tissue sections can be collected for histology or
enzymatic tissue digestion, however accessing human/NHP
tissue is difficult. Lung tissue is easily contaminated with
alveolar/intravascular cells unless the organ is perfused and
BAL collected (however this is not 100% effective). Intravenous
antibody staining can distinguish tissue resident from circulatory
cells, however, is not performed in humans/NHP. TRM/BRM are
identified through surface marker expression or gene signature,Frontiers in Immunology | www.frontiersin.org 9with pathogen-specificity evaluated through intracellular
cytokine staining following exposure to antigen/MHC
tetramers (TRM) or binding of labelled-antigen (BRM). Given
the limited information gained on pulmonary TRM/BRM
populations using current sampling methods, new detection
techniques are required.
In Situ Optical Imaging
Optical endomicroscopy imaging (88), recently used for the
detection of human alveolar neutrophils in situ (89), may
provide a valuable tool for assessing pulmonary-resident
memory lymphocytes and quantifying immunological memory
following vaccination. Fluorescently tagged ligands or antibodies,
capable of binding to specific TRM/BRM surface markers, can be
delivered to the airways via a bronchoscope to enable
visualisation (Figure 3). The information gained can be
combined with systemic data to evaluate vaccine efficacy and
expected degree of protection against respiratory pathogens. In
situ optical imaging may also be used to screen lungs for
transplantation, as the presence of TRM in donor tissue is
associated with reduced adverse clinical events in the
recipient (30).
Ex Vivo Lung Perfusion
The COVID-19 pandemic has highlighted how immune
responses in the airways differ from those in the circulation
and that it is tissues, not blood, where immune cells function
(90). Assessing tissue-based immunity following infection and
vaccination is therefore essential. Ex vivo lung perfusion (EVLP),
using human lungs deemed non-suitable for transplantation,FIGURE 3 | In Situ Optical Imaging of Resident Memory Lymphocytes. Optical endomicroscopy imaging within the lungs may allow for the in situ detection and
quantification of resident memory lymphocyte populations. Monitoring numbers following immunization may help reflect vaccine efficacy and immunological memory.
Fluorescently tagged ligands or antibodies, capable of binding to specific TRM/BRM surface markers, can be delivered to the airways via a bronchoscope to enable
visualisation. Using a combination of fluorescent ligands/antibodies could help differentiate resident memory lymphocyte populations.September 2021 | Volume 12 | Article 738955
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optimising in situ optical imaging. As well as studying
populations in situ, EVLP offers the ability to isolate large
numbers of human TRM/BRM, far higher than those obtained
from a typical BAL, for in-depth analysis (including phenotype,
function, and antigen-specificity). Intraperfusate delivery of a
fluorescently tagged CD45 antibody can also differentiate
circulating (labelled) from tissue-resident (non-labelled) cells.
This technique has recently revealed how human lung TRM
colocalise with lung-resident macrophages, preferentially
around the airways, where they receive costimulatory signals to
augment effector cytokine production and degranulation (91).CONCLUDING REMARKS
Resident memory lymphocytes in the lung enhance immunity
against respiratory pathogens. Understanding the mechanisms
that drive TRM and BRM formation will improve vaccine design,
with the hope of generating long lived, polyfunctional TRM and
broadly reactive, neutralising-antibody-secreting BRM in the
lung. Targeting respiratory APCs with antigen followed by
subsequent “boosts” may establish and maintain these
populations. Assessing the local and systemic responses using a
combination of in situ imaging and peripheral blood samplingFrontiers in Immunology | www.frontiersin.org 10may reveal the efficacy of novel vaccines designed specifically to
induce resident memory lymphocyte populations in the lung.
Human ex vivo lung perfusion provides an ideal model for
researching TRM/BRM populations and optimising novel
methods for their in situ detection to help quantify
immunological memory.AUTHOR CONTRIBUTIONS
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